NEW YORK, March 29, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on EBIO, ECYT, ESPR, and EXEL which can be accessed for free by signing up to www.wallstequities.com/registration. On Wednesday, March 28, 2018, US markets saw five out of nine sectors finishing
On Wednesday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. recorded a trading volume of 1.09 million shares, which was above their three months average volume of 954.20 thousand shares. The stock ended the session flat at $1.02. The Company's shares have gained 11.98% over the previous three months. The stock is trading above its 50-day moving average by 4.72%. Moreover, shares of Eleven Biotherapeutics, which focuses on the design and development of targeted protein therapeutics, have a Relative Strength Index (RSI) of 45.29. Get the full research report on EBIO for free by clicking below at:
West Lafayette, Indiana headquartered Endocyte Inc.'s stock closed the day 1.90% lower at $8.80 with a total trading volume of 1.54 million shares. The Company's shares have advanced 109.52% in the past month, 99.55% in the previous three months, and 277.68% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 56.91% and 141.19%, respectively. Additionally, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have an RSI of 57.12.
On March 09th, 2018, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock, with a target price of $20 per share. Free research on ECYT can be accessed at:
Shares in Ann Arbor, Michigan headquartered Esperion Therapeutics Inc. recorded a trading volume of 605,602 shares. The stock ended yesterday's trading session 0.52% lower at $72.28. The Company's shares have advanced 12.27% over the previous three months and 102.69% in the past twelve months. The stock is trading above its 200-day moving average by 27.22%. Furthermore, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 44.06.
On March 27th, 2018, research firm Chardan Capital Markets reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $75 a share to $100 a share. Sign up today for the free research report on ESPR at:
South San Francisco, California headquartered Exelixis Inc.'s stock finished Wednesday's session 0.36% lower at $22.36 with a total trading volume of 2.95 million shares, which was above their three months average volume of 2.87 million shares. The Company's shares have advanced 5.08% in the past twelve months. The stock is trading below its 50-day moving average by 18.11%. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer, have an RSI of 29.21. Wall St. Equities' research coverage also includes the downloadable free report on EXEL at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----eleven-biotherapeutics-endocyte-esperion-therapeutics-and-exelixis-300621571.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!